Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
about
A Dormant Microbial Component in the Development of PreeclampsiaIron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseasesPotent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering?Low doses of simvastatin therapy ameliorate cardiac inflammatory remodeling in Trypanosoma cruzi-infected dogs.A clinical evaluation of statin pleiotropy: statins selectively and dose-dependently reduce vascular inflammationEvaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial.Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment armsLipid-lowering effects of ezetimibe and simvastatin in combination.The evolution or revolution of statin therapy in primary prevention: where do we go from here?Angina pectoris: current therapy and future treatment options.Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study.Guidelines for Management of Hyperlipidemia: Implications for Treatment of Patients with Stroke Secondary to Atherosclerotic Disease.Pitavastatin further decreases serum high-sensitive C-reactive protein levels in hypertensive patients with hypercholesterolemia treated with angiotensin II, type-1 receptor antagonists.Anti-inflammatory effect of amlodipine plus atorvastatin treatment on carotid atherosclerosis in zucker metabolic syndrome rats.
P2860
Q28069689-61AD275B-3D23-488D-AD3E-31678EAA37DAQ28388335-C4CE7E4C-80B6-41E0-B702-79940459D437Q34255430-1C1829F8-6A4A-4D1F-AF99-610DFF3EF180Q34531351-7CACB0BA-1572-4824-BCE5-ADDCAE8DA2F3Q34562390-35AA06FC-8AC9-4FE3-A04B-E34C741D91A9Q35756468-B679C1E2-C6E0-42D3-AC7F-5769923E7EF1Q36924697-2F1523B0-C876-4F65-ACED-FAD66A642E43Q37859778-FC1DBCD5-C57B-48D9-9896-879106C7C650Q38072612-50640853-9981-438C-9D9D-5CAD1942ED2CQ38177869-A6B84759-9B4B-4E7A-8DC6-C27B4F410FBEQ38471162-60836F16-A45E-41BC-ADCD-25D79FE78394Q38720697-A6658346-D5AF-4811-B78D-8A01D49B8C81Q42844912-726EB51A-4ACC-4432-874F-EE114B3ED584Q46185248-B8974920-3058-4D65-83C8-152A5CBCC5F6
P2860
Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Models for describing relation ...... ects, and cardiovascular risk.
@en
Models for describing relation ...... ects, and cardiovascular risk.
@nl
type
label
Models for describing relation ...... ects, and cardiovascular risk.
@en
Models for describing relation ...... ects, and cardiovascular risk.
@nl
prefLabel
Models for describing relation ...... ects, and cardiovascular risk.
@en
Models for describing relation ...... ects, and cardiovascular risk.
@nl
P921
P1476
Models for describing relation ...... ects, and cardiovascular risk.
@en
P2093
Jennifer G Robinson
P304
P356
10.1016/J.AMJCARD.2007.11.060
P407
P577
2008-04-01T00:00:00Z